CKD-391 DDI : Atorvastatin and Ezetimibe in Healthy Volunteers

March 9, 2015 updated by: Chong Kun Dang Pharmaceutical

CKD-391 in Healthy Volunteers to Investigate the Pharmacokinetic Drug Interaction Between Atorvastatin an Ezetimibe After Oral Administration

A randomized open-label, multiple dose, three-treatment, three-period, six-sequence, crossover study to investigate the pharmacokinetic drug interaction between Atorvastatin and Ezetimibe after oral administration in healthy volunteers

Study Overview

Status

Completed

Conditions

Healthy

Intervention / Treatment

Detailed Description

Outcome Measures

Primary endpoint AUCτ,ss, Cmax,ss of atorvastatin and free ezetimibe
Second endpoint 1) AUCinf,ss, Cavg,ss, %fluctuation, tmax,ss, t1/2, CL/Fss, Vd/Fss of atorvastatin and free ezetimibe 2) AUCτ,ss, AUCinf,ss, Cmax,ss, tmax,ss, t1/2, metabolic ratio of 2-hydroxy atorvastatin and free ezetimibe

Study Type

Interventional

Enrollment (Actual)

Phase

Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Korea, Republic of
- - Seoul, Korea, Republic of
    - ChongKunDang

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years to 45 years (Adult)

Accepts Healthy Volunteers

Genders Eligible for Study

All

Description

Inclusion Criteria:

Age Eligible for Study : 19 Years to 45 Years
If males, Body weight ≥ 55kg, If females, Body weight ≥ 50kg
BSA ≥ 18.5, <25
Accepts healthy volunteers
If female, Negative for pregnancy test at the screening and pre dose of Day 1
The subjects who agree with performing contraception during the study
The subjects who agreed with written informed consent

Exclusion Criteria:

The subjects with impaired hepatic function, renal function, nervous system etc.
The subjects have a gastrointestinal disease or surgery which can be effected in absorption of Investigational product
The subjects with high blood pressure or low blood pressure (Systolic blood pressure>150mmHg or <90mmHg, Diastolic blood pressure>100mmHg or <50mmHg
The subjects with abnormal Laboratory test (AST, ALT>1.25 fold of upper normal limit, Total bilirubin>1.5 fold of upper normal limit, CPK>2 fold of upper normal limit, Estimated Glomerular filtration rate<60mL/min/1.73m2 by Modification of Diet in Renal disease formula
The subjects have drug abuse history within 1year or Positive for urine drug test at screening
The subjects who took prescription only medicine whch can be effected in metabolism of Investigational product within 14days
The subjects who took over the counter drug whch can be effected in metabolism of Investigational product within 7days

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Interventional Model: Crossover Assignment
Masking: None (Open Label)

Number of Arms

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 1(Lipitor®>Ezetrol®>Lipitor®, Ezetrol®) Three treatment atorvastatin calcium 40mg will be administration to healthy volunteers during 7days after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days	Drug: 1 (Lipitor®) atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days Other Names: Lipitor® 40mg Drug: 1 (Ezetrol®) After 11days withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days Other Names: Ezetrol® 10mg Drug: 1 (Lipitor®, Ezetrol®) After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days Other Names: Lipitor® 40mg, Ezetrol® 10mg
Experimental: 2(Ezetrol®>Lipitor®, Ezetrol®>Lipitor®) Three treatment ezetimibe 10mg will be administered to healthy volunteers during 7days after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days	Drug: 2 (Ezetrol®) ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days Other Names: Ezetrol® 10mg Drug: 2(Lipitor®, Ezetrol®) After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days Other Names: Lipitor® 40mg, Ezetrol® 10mg Drug: 2 (Lipitor®) After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days Other Names: Lipitor® 40mg
Experimental: 3(Lipitor®, Ezetrol®>Lipitor®>Ezetrol®) Three treatment atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days	Drug: 3(Lipitor®, Ezetrol®) atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days Other Names: Lipitor® 40mg, Ezetrol® 10mg Drug: 3 (Lipitor®) After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days Other Names: Lipitor® 40mg Drug: 3 (Ezetrol®) After 11day withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days Other Names: Ezetrol® 10mg
Experimental: 4(Lipitor®>Lipitor®, Ezetrol®>Ezetrol®) atorvastatin calcium 40mg will be administered to healthy volunteers during 7days after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days	Drug: 4 (Lipitor®) atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days Other Names: Lipitor® 40mg Drug: 4(Lipitor®, Ezetrol®) After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days Other Names: Lipitor® 40mg, Ezetrol® 10mg Drug: 4 (Ezetrol®) After 11day withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days Other Names: Ezetrol® 10mg
Experimental: 5(Ezetrol®>Lipitor®>Lipitor®, Ezetrol®) ezetimibe 10mg will be administered to healthy volunteers during 7days after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days after 11days withdrawal period, atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days	Drug: 5 (Ezetrol®) ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days Other Names: Ezetrol® 10mg Drug: 5 (Lipitor®) After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days Other Names: Lipitor® 40mg Drug: 5 (Lipitor®, Ezetrol®) After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days Other Names: Lipitor® 40mg, Ezetrol® 10mg
Experimental: 6(Lipitor®, Ezetrol®>Ezetrol®>Lipitor®) atorvastatin calcium 40mg and ezetimibe 10mg will be administered to healthy volunteers during 7days after 11days withdrawal period, ezetimibe 10mg will be administered to healthy volunteers during 7days after 11days withdrawal period, atorvastatin calcium 40mg will be administered to healthy volunteers during 7days	Drug: 6(Lipitor®, Ezetrol®) atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days Other Names: Lipitor® 40mg, Ezetrol® 10mg Drug: 6 (Ezetrol®) After 11days withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days Other Names: Ezetrol® 10mg Drug: 6 (Lipitor®) After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days Other Names: Lipitor® 40mg

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
AUCτ,ss of atorvastatin and free ezetimibe Time Frame: common : just before the IP administration of D5(D22, D39), D6(D23, D40)	Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h	common : just before the IP administration of D5(D22, D39), D6(D23, D40)
Cmax,ss of atorvastatin and free ezetimibe Time Frame: common : just before the IP administration of D5(D22, D39), D6(D23, D40)	Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h	common : just before the IP administration of D5(D22, D39), D6(D23, D40)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
AUCinf,ss of atorvastatin and free ezetimibe Time Frame: common : just before the IP administration of D5(D22, D39), D6(D23, D40)	Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h	common : just before the IP administration of D5(D22, D39), D6(D23, D40)
Cavg,ss of atorvastatin and free ezetimibe Time Frame: common : just before the IP administration of D5(D22, D39), D6(D23, D40)	Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h	common : just before the IP administration of D5(D22, D39), D6(D23, D40)
%fluctuation of atorvastatin and free ezetimibe Time Frame: common : just before the IP administration of D5(D22, D39), D6(D23, D40)	Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h	common : just before the IP administration of D5(D22, D39), D6(D23, D40)
tmax,ss of atorvastatin and free ezetimibe Time Frame: common : just before the IP administration of D5(D22, D39), D6(D23, D40)	Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h	common : just before the IP administration of D5(D22, D39), D6(D23, D40)
t1/2 of atorvastatin and free ezetimibe Time Frame: common : just before the IP administration of D5(D22, D39), D6(D23, D40)	Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h	common : just before the IP administration of D5(D22, D39), D6(D23, D40)
CL/Fss of atorvastatin and free ezetimibe Time Frame: common : just before the IP administration of D5(D22, D39), D6(D23, D40)	Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h	common : just before the IP administration of D5(D22, D39), D6(D23, D40)
Vd/Fss of atorvastatin and free ezetimibe Time Frame: common : just before the IP administration of D5(D22, D39), D6(D23, D40)	Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h	common : just before the IP administration of D5(D22, D39), D6(D23, D40)
AUCτ,ss of 2-hydroxy atorvastatin and total ezetimibe Time Frame: common : just before the IP administration of D5(D22, D39), D6(D23, D40)	Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h	common : just before the IP administration of D5(D22, D39), D6(D23, D40)
AUCinf,ss of 2-hydroxy atorvastatin and total ezetimibe Time Frame: common : just before the IP administration of D5(D22, D39), D6(D23, D40)	Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h	common : just before the IP administration of D5(D22, D39), D6(D23, D40)
Cmax,ss of 2-hydroxy atorvastatin and total ezetimibe Time Frame: common : just before the IP administration of D5(D22, D39), D6(D23, D40)	Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h	common : just before the IP administration of D5(D22, D39), D6(D23, D40)
tmax,ss of 2-hydroxy atorvastatin and total ezetimibe Time Frame: common : just before the IP administration of D5(D22, D39), D6(D23, D40)	Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h	common : just before the IP administration of D5(D22, D39), D6(D23, D40)
t1/2 of 2-hydroxy atorvastatin and total ezetimibe Time Frame: common : just before the IP administration of D5(D22, D39), D6(D23, D40)	Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h	common : just before the IP administration of D5(D22, D39), D6(D23, D40)
metabolic ratio of 2-hydroxy atorvastatin and total ezetimibe Time Frame: common : just before the IP administration of D5(D22, D39), D6(D23, D40)	Atorvastatin single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 h Ezetimibe single : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h Atorvastatin+Ezetimibe : just before the IP administration of D7(D24, D41) and after the IP administration 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96 h	common : just before the IP administration of D5(D22, D39), D6(D23, D40)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Chong Kun Dang Pharmaceutical

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2014

Primary Completion (Actual)

February 1, 2015

Study Completion (Actual)

February 1, 2015

Study Registration Dates

First Submitted

October 30, 2014

First Submitted That Met QC Criteria

November 7, 2014

First Posted (Estimate)

November 11, 2014

Study Record Updates

Last Update Posted (Estimate)

March 10, 2015

Last Update Submitted That Met QC Criteria

March 9, 2015

Last Verified

November 1, 2014

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

152DDI14016

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

University of Vermont Medical Center
Avocado Nutrition Center

Recruiting

Avocado and Postprandial Responses

Healthy | Healthy Volunteers | Healthy Subjects | Healthy Volunteer | Healthy Adult | Healthy Volunteers Only | Healthy Male and Female Subjects | Healthy Non-smokers

United States
Dragonfly Therapeutics

Recruiting

A Study to Evaluate the Safety of Increasing Doses of DF5112 in Healthy Adults (DF5112)

Healthy | Healthy Participants | Healthy Adult Females | Volunteer | Healthy Adult Male

Australia
University of Palermo

Completed

Neck Static Stretching Acutely Reduces Blood Pressure Through Reduction of Tissue Stiffness

Healthy | Healthy Volunteers | Healthy Subjects | Healthy Participants | Static Stretching | Stretch | Stretching

Italy
Prevent Age Resort "Pervaya Liniya"

Recruiting

First Line Prevent Age Study (FLIPS)

Healthy Aging | Healthy Diet | Healthy Lifestyle

Russian Federation
Umm Al-Qura University

Active, not recruiting

Effect of Magnesium Supplementation on Sleep Quality and Cognitive Function in Saudi Adults

Healthy | Healthy Participants | Healthy Adult | Healthy Women | Healthy Adult Females | Healthy Adult Participants | Healthy Young Adults | Healthy Adult Female Participants | Healthy Adult Male | Poor Sleep Quality | Healthy (Controls) | Poor Sleeping Quality | Healthy Adult Male Subjects | Health Adult Subjects

Saudi Arabia
Maastricht University Medical Center

Completed

Reference Gait Data for Healthy Subjects

Healthy Volunteers | Healthy Subjects | Healthy Adults

Netherlands
University of Palermo

Completed

Roller Massage and Blood Pressure

Healthy Participants | Healthy Adult Participants | Healthy Young Adults

Italy
Yale University

Not yet recruiting

Health-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For Health

Healthy Diet | Healthy Lifestyle | Healthy Nutrition | Cholesterol

United States
Pfizer

Not yet recruiting

A Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy Adults

Healthy | Healthy Adults

United States
Atisama Therapeutics

Recruiting

Inhaled RB042 in Healthy Adult Volunteers and Healthy Adult Smokers

Healthy | Healthy Smoker

Australia

Clinical Trials on 1 (Lipitor®)

Makerere University
Vaccine and Gene Therapy Institute, Florida

Completed

Atorvastatin for HAART Suboptimal Responders

Acquired Immune Deficiency Syndrome Virus
Laboratorios Silanes S.A. de C.V.

Recruiting

Efficacy and Safety of the Fixed-dose Combination Atorvastatin/Fenofibrate vs Atorvastatin in Patients With T2D and DLP.

Dyslipidemia Associated With Type II Diabetes Mellitus

Mexico
National Institute of Kidney Disease and Urology...

Completed

Atorvastatin Therapy in the Treatment of Dyslipidemia in Children With Steroid Sensitive Nephrotic Syndrome

Dyslipidaemia

Bangladesh
Teoxane SA

Active, not recruiting

TEOSYAL RHA® 1 for Neck Lines, Perioral Lines and Smiling Lines

Skin Aging | Fine Lines of the Face and Neck

Spain
Université de Montréal

Completed

Peri-Implant Healing Around Two Different Machined-Collar Designs After 25 Years of Function

Jaw, Edentulous

Canada
Alcon Research

Completed

Clinical Evaluation of DAILIES TOTAL 1® Performance in a Japanese Population

Refractive Error

Japan
Revance Therapeutics, Inc.

Active, not recruiting

Teosyal RHA® Histology and Intradermal Implantation Evaluation Study

Histology

Canada
Alcon Research

Completed

Subjective Comparison of Pre-Lens Tear Film Stability With Daily Disposable Contact Lenses

Refractive Error | Myopia | Hyperopia
Shanghai Eye Disease Prevention and Treatment Center

Not yet recruiting

Dual-focus Soft Contact Lenses for Controlling Rapid Progressive Myopia in Young Adults

Myopia

China
Keri Medical SA

Active, not recruiting

Post Market Clinical Follow-Up TOUCH® CMC 1

Osteoarthritis Thumb

France

CKD-391 DDI : Atorvastatin and Ezetimibe in Healthy Volunteers

CKD-391 in Healthy Volunteers to Investigate the Pharmacokinetic Drug Interaction Between Atorvastatin an Ezetimibe After Oral Administration

Study Overview

Status

Conditions

Intervention / Treatment

Detailed Description

Study Type

Enrollment (Actual)

Phase

Contacts and Locations

Study Locations

Participation Criteria

Eligibility Criteria

Ages Eligible for Study

Accepts Healthy Volunteers

Genders Eligible for Study

Description

Study Plan

How is the study designed?

Design Details

Number of Arms

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure

Measure Description

Time Frame

Secondary Outcome Measures

Outcome Measure

Measure Description

Time Frame

Collaborators and Investigators

Sponsor

Study record dates

Study Major Dates

Study Start

Primary Completion (Actual)

Study Completion (Actual)

Study Registration Dates

First Submitted

First Submitted That Met QC Criteria

First Posted (Estimate)

Study Record Updates

Last Update Posted (Estimate)

Last Update Submitted That Met QC Criteria

Last Verified

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Clinical Trials on Healthy

Clinical Trials on 1 (Lipitor®)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations